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OBJECTIVE. To understand the prevalence of multidrug-resistant organism (MDRO) infections among nursing home (NH) residents 
and the potential for their spread between NHs and acute care hospitals (ACHs). 
METHODS. Descriptive analyses of MDRO infections among NH residents using all NH residents in the Long-Term Care Minimum Data 
Set (MDS) 3.0 between October 1, 2010 and December 31, 2011. 
RESULTS. Analysis of MDS data revealed a very high volume of bidirectional patient flow between NHs and ACHs, indicating the need 
to study MDRO infections in NHs as well as in hospitals. A total of 4.24% of NH residents had an active MDRO diagnosis on at least 1 
MDS assessment during the study period. This rate significantly varied by sex, age, urban/rural status, and state. Approximately 2% of NH 
discharges to ACHs involved a resident with an active diagnosis of infection due to MDROs. Conversely, 1.8% of NH admissions from 
an ACH involved a patient with an active diagnosis of infection due to MDROs. Among residents who acquired an MDRO infection 
during the study period, 57% became positive in the NH, 41% in the ACH, and 2% in other settings (eg, at a private home or apartment). 
CONCLUSION. Even though NHs are the most likely setting where residents would acquire MDROs after admission to an NH (accounting 
for 57% of cases), a significant fraction of NH residents acquire MDRO infection at ACHs (41%). Thus, effective MDRO infection control 
for NH residents requires simultaneous, cooperative interventions among NHs and ACHs in the same community. 
Infect Control Hosp Epidemiol 2014;35(S3):S48-S55 
Healthcare-associated infections (HAIs) are infections that (extended-spectrum /3-lactamase-producing gram-negative 
patients acquire during the course of receiving healthcare bacilli [ESBL] and fluoroquinolone-resistant P. aeruginosa). 
treatment for other conditions. The Centers for Disease Con- The prevalence of MDROs in medical centers has increased 
trol and Prevention estimated that the 1.74 million HAIs steadily.5 Older patients are among the main reservoirs of 
reported in 2007 cost US hospitals between $28.4 and $33.8 MDROs in the hospital. In a study conducted in a 620-bed 
billion.1 In response, the US government instituted policy tertiary care healthcare facility in Boston, admission preva-
changes to reduce the incidence of HAIs. Under the Afford- lence per 1,000 for MRSA, VRE, and multidrug-resistant 
able Care Act, states were required to start reporting their gram-negative bacteria (MDRGN) was consistently higher 
rates of HAIs in 2012.2 Beginning in 2015, hospitals in the among the elderly population than among other age groups, 
quartile with the highest number of HAIs will have their Furthermore, admission prevalence among the elderly pop-
Medicare payments reduced by 1%.3 ulation increased significantly over time for VRE (from 0.89 
Two-thirds of all HAIs come from just 6 multidrug-resis- cases per 1,000 admissions in 1998 to 3.62 cases per 1,000 
tant organisms (MDROs).4 These include Enterococcusspecies admissions in 2009) and MDRGN (1.41 cases per 1,000 ad-
(vancomycin-resistant enterococci [VRE]), Staphylococcus missions in 1998 to 11.33 cases per 1,000 admissions in 2009). 
aureus (methicillin-resistant S. aureus [MRSA], vancomycin- The admission prevalence of MRSA increased until 2003 and 
intermediate S. aureus [VISA], or vancomycin-resistant S. then decreased (6.6 cases per 1,000 admissions in 1998, 24.8 
aureus [VRSA]), Klebsiella pneumoniae, Acinetobacter bau- in 2003, and 16.3 in 2009).6 
mannii, Pseudomonas aeruginosa, and Enterobacter species It is not surprising that MDROs are also a serious concern 
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TABLE 1. Distribution of Nursing Home Residents by Demographic Characteristic and 
Prevalence of Multidrug-Resistant Organisms (MDROs) among Residents in Each 
Category 
Demographic characteristic 
Total 
Age, years 
Mean ± SD 
<17 
18-29 
30-39 
40-49 
50-54 
55-60 
60-64 
65-69 
70-74 
75-79 
80-84 
85-89 
90-94 
95-99 
>100 
Sex 
Male 
Female 
Race/ethnicity 
White 
Black 
Hispanic 
Asian 
American Indian or Alaska Native 
Native Hawaiian/ Pacific Islander 
Marital status 
Never married 
Married 
Widowed 
Separated 
Divorced 
Urban/rural 
Urban 
Rural 
Overall 
Overall nursing 
home resident population 
100 (4,165,596) 
77.43 ± 13.36 
0.17 (7,153) 
0.35 (14,617) 
0.69 (28,549) 
2.28 (95,167) 
2.78 (115,682) 
4.13 (171,955) 
5.73 (238,778) 
7.95 (331,122) 
9.92 (413,202) 
13.36 (556,487) 
17.88 (744,769) 
18.63 (775,809) 
11.56 (481,576) 
3.90 (162,413) 
0.67 (27,950) 
35.93 (1,496,203) 
64.07 (2,668,462) 
80.04 (3,328,527) 
10.92 (454,213) 
4.34 (180,630) 
1.50 (62,364) 
0.39 (16,322) 
0.30 (12,291) 
14.25 (576,833) 
30.54 (1,236,230) 
43.04 (1,741,940) 
1.33 (53,955) 
10.84 (438,704) 
81.15 (3,380,273) 
18.85 (785,323) 
100 (4,165,596) 
Residents who 
ever received 
a diagnosis 
involving MDRO 
4.24 (176,806) 
74.81 ± 14.22 
3.54 (253) 
7.12 (1,041) 
7.52 (2,148) 
6.76 (6,431) 
5.90 (6,821) 
5.46 (9,388) 
5.16 (12,328) 
4.94 (16,354) 
4.56 (18,839) 
4.25 (23,654) 
3.99 (29,681) 
3.71 (28,759) 
3.28 (15,801) 
2.89 (4,701) 
2.11 (591) 
5.24 (78,413) 
3.69 (98,355) 
4.25 (141,353) 
4.22 (19,148) 
4.16 (7,509) 
3.70 (2,309) 
5.18 (845) 
4.21 (517) 
4.87 (28,074) 
4.47 (55,302) 
3.69 (64,364) 
4.87 (2,626) 
4.82 (21,148) 
4.38 (148,133) 
3.65 (28,673) 
4.24 (176,806) 
NOTE. Data are percentage (no.) of residents, unless otherwise indicated. SD, standard 
deviation. 
in long-term care settings, especially those that serve the frail 
elderly population.7 In a screening performed in a 120-bed 
skilled nursing facility in the absence of a clinical "outbreak," 
43% of residents were found to be carrying a drug-resistant 
organism. Once introduced in a long-term care facility 
(LTCF), MDROs tend to become endemic.8 Having stayed in 
a LTCF is a risk factor for invasive MRSA infection. In a study 
of patient intake forms at a 980-bed tertiary care hospital 
between 1996 and 1997, patients admitted from nursing 
homes (NHs) were 6.4 times more likely to have MRSA than 
those who had come to the hospital from other places.9 NHs 
often have a higher prevalence of MRSA colonization than 
hospitals and ICUs.1011 More than half the residents of LTCFs 
are thought to harbor MDRGN.1214 
It is important to distinguish between colonization and 
clinical infection. Colonization is an asymptomatic presence 
TABLE 2. Distribution of Nursing Home Residents by State and Prevalence of 
Multidrug-Resistant Organisms (MDROs) among Residents in Each State 
Percentage (no.) of residents 
Residents who ever received 
State Overall nursing home population a diagnosis involving MDRO 
AK 
AL 
AR 
AZ 
CA 
CO 
CT 
DC 
DE 
FL 
GA 
HI 
IA 
ID 
IL 
IN 
KS 
KY 
LA 
MA 
MD 
ME 
MI 
MN 
MO 
MS 
MT 
NC 
ND 
NE 
NH 
NJ 
NM 
NV 
NY 
OH 
OK 
OR 
PA 
RI 
SC 
SD 
TN 
TX 
UT 
VA 
VT 
WA 
WI 
WV 
WY 
Overall 
0.03 (1,436) 
1.53 (63,752) 
0.96 (40,194) 
1.49 (62,224) 
8.66 (360,918) 
1.28 (53,262) 
1.89 (78,671) 
0.16 (6,732) 
0.31 (13,009) 
6.65 (276,989) 
2.04 (84.792) 
0.28 (11,511) 
1.35 (56,202) 
0.38 (15,852) 
4.97 (207,050) 
2.56 (106,604) 
1.05 (43,914) 
1.54 (64,308) 
1.24 (51,722) 
3.24 (134,782) 
2.01 (83,589) 
0.54 (22,527) 
3.25 (135,188) 
2.09 (86,946) 
2.31 (96,317) 
0.84 (34,932) 
0.31 (12,814) 
2.74 (114,340) 
0.30 (12,396) 
0.79 (32,957) 
0.47 (19,376) 
3.72 (155,099) 
0.44 (18,274) 
0.51 (21.103) 
6.93 (288,786) 
5.75 (239,316) 
1.11 (46,137) 
0.87 (36,145) 
5.75 (239,505) 
0.55 (22,713) 
1.22 (50,877) 
0.32 (13,323) 
2.13 (88,575) 
5.79 (241,067) 
0.60 (24,825) 
2.26 (93,947) 
0.21 (8,823) 
1.7 (70,848) 
2.13 (88,687) 
0.63 (26,431) 
0.14 (5,809) 
100 (4,165,596) 
5.92 
1.87 
3.13 
4.49 
4.05 
2.41 
5.67 
3.46 
4.40 
4.05 
2.86 
2.88 
3.64 
3.69 
5.42 
3.20 
3.38 
4.42 
2.49 
6.15 
5.43 
3.25 
3.69 
3.86 
3.31 
2.42 
2.95 
3.34 
5.17 
3.91 
5.85 
4.86 
2.99 
6.33 
4.41 
4.74 
2.19 
2.77 
5.68 
11.42 
2.54 
3.73 
3.55 
3.21 
2.40 
6.34 
6.28 
4.52 
3.75 
7.80 
2.34 
4.24 
85) 
1,192) 
1,259) 
2,794) 
14,610) 
1,285) 
4,461) 
233) 
572) 
11,231) 
2,426) 
331) 
2,048) 
585) 
11,231) 
3,414) 
1,484) 
2,840) 
1,286) 
8,289) 
4,540) 
733) 
4,984) 
3,354) 
3,190) 
847) 
378) 
3,822) 
641) 
1,290) 
1,134) 
7,534) 
546) 
1,335) 
12,749) 
11,351) 
1,009) 
1,003) 
13,612) 
2,593) 
1,292) 
497) 
3,147) 
7,736) 
595) 
5,958) 
554) 
3,204) 
3,324) 
2,062) 
136) 
176,806) 
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TABLE 3. Distribution of Nursing Home Residents by US Census 
Bureau Region and Division and Prevalence of Multidrug-Resistant 
Organisms (MDROs) among Residents in Each Region and Division 
Percentage (no.) of residents 
Residents who 
ever received 
Overall nursing a diagnosis 
Geographic area home population involving MDRO 
Census region 
Midwest 
Northeast 
South 
West 
:nsus division 
Midwest 
West North Central 
East North Central 
Northeast 
Middle Atlantic 
New England 
South 
West South Central 
East South Central 
South Atlantic 
West 
Mountain 
Pacific 
verall 
26.86 (1,118,900) 
23.29 (970,282) 
33.16 (1,381,393) 
16.68 (695,021) 
8.21 (342,055) 
18.65 (776,845) 
16.41 (683,390) 
6.89 (286,892) 
9.10 (379,120) 
6.04 (251,567) 
18.02 (750,706) 
5.14 (214,163) 
11.54 (480,858) 
100 (4,165,596) 
4.18 (46,808) 
5.32 (51,659) 
3.72 (51,452) 
3.87 (26,887) 
3.66 (12,504) 
4.42 (34,304) 
4.96 (33,895) 
6.19 (17,764) 
2.98 (11,290) 
3.19 (8,026) 
4.28 (32,136) 
3.57 (7.654) 
4.00 (19,233) 
4.24 (176,806) 
of pathogenic bacteria in culture specimens. Clinical guide-
lines for managing infections in LTCFs suggest that, in most 
cases, colonization with no clinical symptoms of infection 
should not be treated, to minimize the risk of creating 
MDROs. Clinical infections (ie, those that exhibit symptoms) 
should be treated in most cases.1516 Furthermore, MDRO-
colonized LTCF residents can eventually exhibit symptoms 
that require treatment according to guidelines17 and can be-
come the source of transmission to other healthcare set-
tings.1828 
The increasing prevalence of clinical MDRO infections is 
associated with increased lengths of stay, costs, and mortal-
ity.29 The demand for places in LTCFs will grow substantially 
in the next 2 decades as the large population cohort born 
before 1964 ages. It is estimated that people using paid LTCFs 
will double to 27 million by 2050.30 Thus, the cost and quality 
of care, the risk of HAIs, and the prevalence of MDROs in 
LTCFs are important issues for society. 
There are several gaps in the literature. First, the literature 
does not examine the patterns of transmission to and from 
LTCFs and ACHs. Second, few earlier studies reported on the 
racial or geographic disparities in MDRO prevalence. Third, 
we were not able to find any study that described the trans-
mission of the infection and its pattern of transmission across 
settings. 
M E T H O D S 
This study uses the Centers for Medicare and Medicad Ser-
vices (CMS) Long Term Care Minimum Data Set (MDS).3' 
MDS is a standardized, primary screening and assessment 
tool that measures physical, clinical, psychological, and psy-
chosocial functional status and life care wishes of all residents 
(regardless of payer) of Medicare- or Medicaid-certified NHs. 
MDS data include a resident-level active MDRO infection 
indicator measured at admission and periodically thereafter 
(at least quarterly), the type of setting from which the resident 
is admitted, and the type of setting to which the resident is 
discharged. These settings include community (private home 
or apartment, board or care, assisted living, and group home), 
another NH or swing bed facility, ACH, psychiatric hospital, 
inpatient rehabilitation facility, intellectual disability or de-
velopmental disability facility, hospice, and long-term care 
hospital. Although it would be desirable to study the rates of 
both asymptomatic and symptomatic infections, the MDS 
captures only clinically symptomatic infections. Although it 
would be useful to include all types of LTCFs in the study, 
MDS data are collected only in Medicare- and Medicaid-
certified NHs. 
For this study, we used national MDS data for 15 months 
from October 1, 2010, through December 31, 2011. During 
this period, there were 135 days, on average, between MDS 
assessments, with a median of 51 days. There were approx-
imately 16,000 facilities with at least 1 MDS record. There 
was at least 1 assessment record for 4,165,596 residents. On 
average, residents had 4.6 assessments with a median of 4 
during this time period. 
Our analysis sought to address the following 6 research 
questions: (1) What is the frequency of NH admissions from 
ACHs and discharges to ACHs? (2) What percentage of hos-
pital episodes involving adults (more than 65 years old) in 
the United States in 2011 were either immediately preceded 
by an NH discharge to the hospital or immediately succeeded 
by admission to an NH? (3) What is the national overall 
prevalence of MDRO infections among NH residents, and 
are there demographic or geographic disparities? (4) How 
many NH admissions and discharges from hospitals are of 
individuals who have MDRO infections? (5) How many NH 
residents acquire MDRO infections after NH admission? (6) 
How long does it take for NH residents to acquire MDRO 
infections in NHs? 
We used quantitative descriptive analysis to calculate prev-
alence across a number of strata. We also developed 2 al-
gorithms to identify the possible source setting of the infec-
tion and define a unit of observation for analyzing the onset 
of the infection. The counts and rates reported are for the 
US population of NH residents during the period October 
1, 2010, through December 31, 2011. Because control of 
MDROs is a major patient safety initiative for NHs and hos-
pitals nationwide, we expect these rates to improve with time. 
Thus, we are reluctant to imply that they reflect a larger 
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TABLE 4. Multidrug-Resistant Organism (MDRO) Data by Quarter 
Baseline quarter Follow-up quarter 1 Follow-up quarter 2 Follow-up quarter 3 
(average start date: (average start date: (average start date: (average start date: 
Study cohort (sample size = 720,788) mid-November 2010) mid-February 2011) mid-May 2011) mid-August 2011) 
MDRO infection prevalence 
MDRO infection rate (new infections) 
among residents with no infection 
reported at baseline 
Cumulative MDRO infection rate 
among residents with no infection 
reported at baseline 
1.38 1.34 
0.70 
0.70 
1.26 
0.80 
1.31 
1.32 
0.93 
1.92 
population of persons who might reside in NHs at other time 
periods and have accordingly chosen to treat the residents of 
US NHs during this period as a finite census population. As 
is appropriate for a finite census, we have not computed 
variances or tested for the statistical significance of the dif-
ferences observed between population groups. These rates 
have not been reported previously and serve as a baseline 
against which future counts and estimates from other sources 
can be compared. 
RESULTS 
Transitions between NHs and ACHs 
During the 15-month study period, there were 2,102,128 dis-
charges from NHs to ACHs for 1,279,608 unique NH resi-
dents. These discharges represent 45% of all discharges from 
NHs and 30.7% of all residents who were discharged at least 
once. 
During this period, 90% of all admissions to NHs 
(4,399,280 admissions) came from ACHs. Approximately 
2,914,705 NH residents (62.1% of all residents) were admitted 
to an NH immediately after discharge from ACHs. 
To understand what these results could mean for all hos-
pitals, we extrapolated the study's findings to data from the 
Agency for Healthcare Research and Quality's (AHRQ's) 
Healthcare Cost and Utilization Project (HCUP). AHRQ's 
HCUP reports that there were a total of 13,816,586 discharges 
of older adults from all hospitals in the United States in 2011. 
According to our calculations from MDS data for the same 
period, at least 2,965,678 of such hospital episodes (21.5%) 
were either immediately preceded by an NH discharge to the 
hospital or immediately succeeded by admission to an NH. 
Such hospital episodes were experienced by 2,046,501 NH 
residents (69%) who were 65 years of age and older. 
These findings show that there is a very high volume of 
patient flow between NHs and hospitals. This indicates dra-
matic potential of MDRO transmission across these settings. 
Thus, MDRO infections in NHs are expected to have strong 
implications for MDRO infections in hospitals. 
Prevalence of MDROs 
As displayed in Table 1, 4.24% of NH residents had a MDRO 
on at least 1 assessment during their NH stay. Male residents 
had a higher rate of infection than female residents (5.24% 
and 3.69%, respectively). American Indian and Alaska Natives 
had the highest rate of infection at 5.18%, and Asians had 
the lowest rate (3.70%). Infection rate by marital status varied 
by just over 1%, with the lowest rate among widowed resi-
dents (3.69%) and the highest rate among never married and 
separated residents (both at 4.87%). Residents in an urban 
setting had a rate of 4.28%, and those in a rural setting had 
a rate of 3.65%. 
The rate of infection in NHs varied by age group, with the 
lowest prevalence among the oldest residents (those over 100 
years old) at 2.11% and the highest among those 30-39 years 
old (7.52%) and 18-29 years old (7.12%). The age bands that 
represented the largest proportions of the population were 
75-79 years old (13.36%), 80-84 years old (17.88%), 85-89 
years old (18.63%), and 90-94 years old (11.56%), and prev-
alence in these groups was 4.25%, 3.99%, 3.71%, and 3.28%, 
respectively. 
As Table 2 shows, there was a large variation in MDRO 
prevalence among the states, with nearly 11 percentage points 
separating the state with the lowest prevalence (Alabama, at 
1.87%) and the state with the highest prevalence state (Rhode 
Island, at 11.42%). 
In addition to large variations between states, there were 
also regional variations, as exhibited in Table 3. The Northeast 
was the only region with MDRO prevalence above the na-
tional rate (5.32% vs 4.24%). Of the remaining 3 regions, the 
South had the lowest prevalence at 3.72%, the West had a 
prevalence of 3.87%, and the Midwest, at 4.18%, had a prev-
alence around the national average. 
Looking at more granular data reveals divisions that are 
driving the Regional results. The South's low prevalence was 
fairly uniform across its 3 divisions (ie, West South Central, 
East South Central, and South Atlantic). The West South 
Central Division within the South had the lowest prevalence 
at 2.98%, with East South Central immediately behind at 
3.19%. The South Atlantic was at 4.28%, close to the national 
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rate. However, at the other end of the spectrum, the division 
with highest prevalence (New England, at 6.19%) was the 
main reason that the Northeast Region had the highest prev-
alence among the regions. Within New England, all but 1 of 
the 6 States had very high prevalences. 
MDRO Acquisition Rates 
The acquisition of MDROs in NHs can be measured by iden-
tifying residents who were MDRO negative at their first as-
sessment after admission to the NH and MDRO positive at 
a subsequent assessment, or those who were MDRO positive 
at their first assessment after admission but for whom the 
time between admission and first assessment is longer than 
7 days. We estimated the frequency of MDRO acquisition in 
ACHs by identifying residents who were already MDRO pos-
itive on their first assessment after readmission to the NH 
from the hospital and for whom the time between the read-
mission date and the date of the first assessment is shorter 
than or equal to 7 days. If residents were already MDRO 
positive at their first assessment, which was usually admin-
istered several days after the readmission to the NH, it is 
difficult to identify whether the MDRO onset occurred after 
returning to the NH or before returning. We therefore re-
quired a "clean period" of 7 days. If residents stayed in the 
NH more than 7 days and were MDRO positive at their first 
assessment in the NH, then we attributed the acquisition of 
MDRO to the NH; on the contrary, if their stay in NH before 
the first assessment was shorter than 7 days and they were 
MDRO positive at the first assessment, we attributed the ac-
quisition of MDRO to other settings outside the NH. The 
method of estimating acquisition rates in the NHs is reason-
ably precise, because residents resided only at the NH during 
the period they converted from negative to positive. Our 
estimates of acquisition in the hospital are less precise, be-
cause it is possible that the resident acquired infection be-
tween the last assessment before transfer to the hospital or 
after returning to the NH following discharge from the hos-
pital. A more precise estimate of hospital acquisition would 
require the ability to link NH assessment and hospital ad-
mission and discharge records for specific residents, which 
was not possible in this study. Nevertheless, with this caveat, 
these estimates provide a useful comparison between NH and 
ACH acquisition of MDROs by NH residents. 
Among the 176,806 residents who had an active MDRO 
infection in the NH at any time during the study period, 61% 
(108,065) transitioned from "no infection" (coded as 0) to 
"infection" (coded as 1). Of those 108,065 residents who had 
a change in infection status from 0 to 1, we found that 57% 
had the change occur in the NHs, 41% had the change occur 
in the ACHs, and 2% had the change occur in other settings. 
Even though the leading source of infections seems to be 
NHs, ACHs are not too far behind. 
To assess the onset of MDRO infections, a cohort of res-
idents were specified for whom consecutive assessments were 
available throughout the study period. It is critical to define 
a period (ie, observation unit for a resident) in which MDRO 
infection indicator can be specified consistently across resi-
dents and over time. Defining an observation unit for out-
come variables such as "ever reported to have an MDRO 
infection" is challenging. There are a variety of reasons for a 
resident to be assessed at various time points. Additionally, 
many residents will not be observed during the entire study 
period, because they may be outside of NHs for 1 or more 
times. There is no readily available consistent observation 
unit. Therefore, we created an observation unit from the 
timing of assessments of all kinds. MDRO infection was in-
cluded in all assessments. Because each resident is supposed 
to have at least a quarterly assessment, we defined our unit 
of observation to be a quarter per resident. For most residents, 
the analysis quarters were determined by the dates of con-
secutive quarterly assessments. For others, 1 or more analysis 
quarters were defined by a combination of various assess-
ments at different times, such as 14-day, 30-day, 60-day, quar-
terly, admission, or discharge assessments. These residents 
have multiple assessments contributing to the quarterly 
MDRO infection indicator. This method is more accurate in 
capturing residents with an MDRO infection in a quarter 
than a method that only looks at MDRO status at a single 
point in time. 
An analysis quarter is defined to be at least 77 days and 
at most 107 days. This is consistent with the MDS manual, 
which indicates that quarterly assessments can be done up 
to 2 weeks sooner. One hundred and seven days is approx-
imately 2 weeks longer than a calendar quarter. Two alter-
native definitions (up to zero days longer and up to 1 week 
longer) were tested, but the results did not change 
significantly. 
Even though CMS data covers all resident assessments done 
in the 5 calendar quarters, very few residents will have as-
sessments covering the full 5 quarters. These are the ones 
who have been residents in each of the 5 quarters, had at 
least a total of 6 assessments in the study period (2 dates 
defines a quarter), and 2 of these assessments occurred at the 
very beginning of the first quarter and at the very end of the 
fifth quarter. The majority will have at most 4 quarters of 
assessments. So, the longitudinal data we created include 4 
quarters, which allows for 1 baseline quarter and 3 follow-
up quarters (Table 4). Of the 4,165,596 residents having at 
least 1 assessment in the study period, only 1,009,170 (24.2%) 
had the minimum necessary number of days between their 
first and last assessments (308 days). Of the 1,009,170 resi-
dents, 730,899 (72.4%) had 5 assessments separated by at 
least 77 days and at most 107 days. 
Quarterly MDRO infection prevalence stayed steady with 
a slight decrease from 1.38% to 1.32% in 4 quarters. By the 
end of the first quarter, 0.70% of residents with no reported 
MDRO infections at baseline were reported to have MDRO 
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infections. This new infection rate increased to 0.80% and 
0.93% in the second and third quarters. By the end of the 
third quarter, almost 2% of residents with no reported MDRO 
infections at baseline were reported to have at least 1 episode 
of MDRO infection. 
D I S C U S S I O N 
This article explores the utility of MDS data for answering a 
number of important research and policy questions around 
prevalence and transmission of MDRO infections across care 
settings. Our findings show that there is a very high-volume 
patient flow between NHs and hospitals. At least 21.5% of 
all older adults' national hospital episodes involve an ad-
mission from or a discharge to an NH. Therefore, MDRO 
infections in one setting will have implications for MDRO 
infections in the other setting. 
We have demonstrated that the MDS data capture useful 
demographic, clinical, and care transition data for hospital 
admissions and discharges. There are signification variations 
in MDRO infection prevalence in NHs across sex, age, and 
geographical groups. Findings include that, in NHs, male 
residents and younger residents are significantly more likely 
to have an active MDRO infection than are female residents 
and older residents. NHs in urban areas experience higher 
infection rates than do their rural counterparts. We have also 
demonstrated that MDS data can be used to assess MDRO 
transmissions across care settings. With MDS data from a 
longer time period, it is possible to better isolate the care 
setting in which MDRO infection onsets. Our findings in-
dicate that MDRO infections are most likely to originate at 
NHs, followed by ACHs. 
We recommend that MDS data be used as a monitoring 
tool and be combined with other data sets, such as HCUP, 
to provide a more complete picture of HAI transmissions 
across care settings to inform development of guidelines for 
prevention of HAIs. 
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